Codexis, Inc.
CDXS Healthcare Biotechnology
Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.
Follow CDXS
Codexis, Inc. (CDXS) EV/Sales
As of 15 October 2026, Codexis, Inc. (CDXS) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from 0.4× (September 2023) to 25.7× (November 2021); the current reading is higher than 6% of that period. That is below the Biotechnology industry median of 9.4× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | (71.41%) |
| FY2024 | 5.1× | 125.17% |
| FY2023 | 2.3× | 38.22% |
| FY2022 | 1.7× | (91.10%) |
| FY2021 | 18.6× | 9.85% |
| FY2020 | 16.9× | 38.16% |
| FY2019 | 12.2× | (9.46%) |
| FY2018 | 13.5× | 95.22% |
| FY2017 | 6.9× | 105.56% |
| FY2016 | 3.4× | (2.81%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.4× | 50.76% |
| Mar 2026 | 1.6× | 7.04% |
| Dec 2025 | 1.5× | (61.24%) |
| Sep 2025 | 3.8× | 19.86% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NBP NovaBridge Biosciences compare | −3.7× |
| MSLE Satellos Bioscience Inc. compare | n/m |
| NKTX Nkarta, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| MENS Jyong Biotech Ltd. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| CDXS Codexis, Inc. | 1.3× |
| CUE Cue Biopharma, Inc. compare | 2.7× |
| MOLN Molecular Partners AG Sponsored ADR compare | 10.1× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)